IP Library › Granted Patent US 12,221,425
Granted Patent B2
US 12,221,425 · App. 17/619,312 · Granted Feb 11, 2025

Process for the preparation of CIC-1 chloride channel inhibitors

Inventors: Nicholas Kelly (Bagsværd, DK); Michael John McKenzie (Leicester, GB)
Assignee: NMD PHARMA A/S
C07D261/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,221,425
App. No.
17/619,312
Granted
Feb 11, 2025
Kind
B2
Abstract

This disclosure relates to an improved chemical process for making compounds which are CIC-1 chloride channel inhibitors.

Claims (202)

1. A process for the preparation of compounds of Formula I

comprising step a) reacting

i) a compound of Formula II with an acid or base

 to form a reaction mixture and

ii) isolating a compound of Formula I from the reaction mixture,

wherein

R 1 is selected from the group consisting of H, F, Cl, Br and I;

R 2 is selected from the group consisting of C1-5 alkyl and C3-5 cycloalkyl;

R 3 is selected from the group consisting of deuterium, F, Cl, Br and I;

R 4 is selected from the group consisting of H, deuterium, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-5 cycloalkyl and C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R 7 ;

R 5 is selected from the group consisting of C1-5 alkyl optionally substituted with one or more, identical or different, substituents R 8 , C2-5 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R 8 , phenyl optionally substituted with one or more, identical or different, substituents R 9 and benzyl optionally substituted with one or more, identical or different, substituents R 9 ;

R 6 is selected from the group consisting of H, deuterium C1-5 alkyl and C3-5 cycloalkyl;

R 7 is independently selected from the group consisting of deuterium, tritium,

F, Cl, Br, I, CN, isocyanide, C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R 8 , O—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 , S—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 , CH2-O—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 ; and CH2-S—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 ;

R 8 is independently selected from the group consisting of deuterium and F;

R 9 is independently selected from the group consisting of deuterium, methoxy, nitro, cyano, Cl, Br, I and F; and

n is an integer 0, 1, 2 or 3.

2. The process of claim 1 , wherein R 1 is Cl or Br.

3. The process of claim 1 , wherein R 2 is C1-5 alkyl.

4. The process of claim 1 , wherein R 3 is F.

5. The process of claim 1 , wherein R 4 is C1-5 alkyl optionally substituted with one or more, identical or different, substituents R 7 .

6. The process of claim 1 , wherein R 5 is C1-5 alkyl optionally substituted with one or more, identical or different, substituents R 8 .

7. The process of claim 1 , wherein R 6 is H.

8. The process of claim 1 , wherein n=0.

9. The process of claim 1 , including reacting the compound of Formula II with an acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid, benzoic acid, hydrochloric acid and sulfuric acid or a mixture thereof.

10. The process of claim 1 , wherein step a) i) is performed at a temperature of between 70° C. and 140° C.

11. The process of claim 1 , wherein the reaction time of step a) i) is between 12 hours and 96 hours.

12. The process of claim 1 , wherein the compound of Formula I is isolated from the reaction mixture in step a) ii) by adding water and extracting a product into an organic solvent.

13. The process of claim 1 , wherein the compound of Formula I is an inhibitor of the CIC-1 chloride ion channel.

14. The process of claim 1 , wherein the process further comprises step b)

i) Reacting a compound of Formula III

 with /V-chlorosuccinimide in an organic solvent to form a reaction mixture;

ii) adding a compound of Formula IV

 and a base to the reaction mixture; and

iii) isolating a compound of Formula II from the reaction mixture, wherein R 1 to R 9 and n are as defined as in claim 1 .

15. A compound selected from the group consisting of:

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl) phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate,

ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(5-methyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(5-cyclopropyl-4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

methyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

methyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; methyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

methyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

methyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

methyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

ethyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

ethyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; ethyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate,

ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

ethyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

ethyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

ethyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

tert-butyl 2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

tert-butyl 2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-butyl (2S)-2-[4,5-dichloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl) phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-5-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

tert-butyl (2S)-2-[4-fluoro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate,

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-butoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bro o-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

methyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

methyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; methyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

methyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

methyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

methyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

ethyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

ethyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; ethyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

ethyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

ethyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate,

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

ethyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-S-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-2-cyclopropylacetate;

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclobutylpropanoate;

tert-butyl 2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate;

tert-butyl 2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]acetate; tert-butyl (2S)-2-[4,5-dichloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-5-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

tert-butyl (2S)-2-[4-fluoro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

tert-butyl (2S)-2-[4-chloro-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-cyclopropylpropanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]butanoate;

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]-3-methylbutanoate; and

tert-butyl (2S)-2-[4-bromo-2-(4-ethoxy-4,5-dihydroisoxazol-3-yl)phenoxy]propanoate.

16. A process for the preparation of a pharmaceutical composition comprising the steps of

i) preparing a compound selected from the group consisting of

(2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]-2-cyclopropylacetic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclobutylpropanoic acid; 2-[4-bromo-S-fluoro-2-(1,2-oxazol-3-yl)phenoxy]acetic acid,

2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]acetic acid;

(2S)-2-[4,5-dichloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-bromo-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-chloro-5-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-fluoro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-chloro-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid;

(2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid;

(2S)-2-[4-chloro-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-cyclopropylpropanoic acid; (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid;

(2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid;

(2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid;

(2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid; and (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid, by

a) reacting

i) a compound of Formula II with an acid or base

 to form a reaction mixture and

ii) isolating a compound of Formula I

 from the reaction mixture,

wherein

R 1 is selected from the group consisting of H, F, Cl, Br and I;

R 2 is selected from the group consisting of C1-5 alkyl and C3-5 cycloalkyl;

R 3 is selected from the group consisting of deuterium, F, Cl, Br and I,

R 4 is selected from the group consisting of H, deuterium, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-5 cycloalkyl and C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R 7 ;

R 5 is selected from the group consisting of C1-5 alkyl optionally substituted with one or more, identical or different, substituents R 8 , C2-5 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl optionally substituted with one or more, identical or different, substituents R 8 , phenyl optionally substituted with one or more, identical or different, substituents R 9 and benzyl optionally substituted with one or more, identical or different, substituents R 9 ,

R 6 is selected from the group consisting of H, deuterium C1-5 alkyl and C3-5 cycloalkyl;

R 7 is independently selected from the group consisting of deuterium, tritium,

 F, Cl, Br, I, CN, isocyanide, C3-5 cycloalkyl optionally substituted with one or more, identical or different, substituents R 8 , O—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 , S—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 , CH2-O—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 and CH2-S—C1-3 alkyl optionally substituted with one or more, identical or different, substituents R 8 ;

R 8 is independently selected from the group consisting of deuterium and F;

R 9 is independently selected from the group consisting of deuterium,

methoxy, nitro, cyano, Cl, Br, I and F; and

n is an integer 0, 1, 2 or 3;

and

ii) formulating said compound of Formula I into a pharmaceutical composition.

17. The process of claim 9 further including wherein the compound of Formula I is isolated from the reaction mixture in step a) ii) by adding water and extracting a product into an organic solvent.

18. The process of claim 17 further comprising step b)

i) reacting a compound of Formula III

 with/V-chlorosuccinimide in an organic solvent to form a reaction mixture;

ii) adding a compound of Formula IV

 and a base to the reaction mixture; and

iii) isolating a compound of Formula II from the reaction mixture.

19. The process of claim 12 further comprising step b)

i) reacting a compound of Formula III

 with /V-chlorosuccinimide in an organic solvent to form a reaction mixture;

ii) adding a compound of Formula IV

 and a base to the reaction mixture; and

iii) isolating a compound of Formula II from the reaction mixture.

20. The process of claim 1 including wherein R 2 is C1-5 alkyl, R 3 is F, and R 4 is C1-5 alkyl optionally substituted with one or more, identical or different, substituents R 7 .

21. The process of claim 1 , wherein the compound of Formula II is reacted with a base.

22. The process of claim 1 , wherein the compound of Formula I is purified by crystallisation from an organic solvent selected from the group consisting of toluene, ethyl acetate, isopropyl acetate, and tert-butyl methyl ether.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2022
From: KELLY, NICHOLAS; MCKENZIE, MICHAEL JOHN
To: NMD PHARMA A/S
Reel/Frame 058788/0458 →
Priority Claims (1)
EP 19181262 · Jun 19, 2019 · regional
Continuity (1)
Related Publication 20220298124A1 · Sep 22, 2022
References Cited (5)
US 10385028B2 · Knutsen · 2019 [cited by examiner]
WO 2016202341A1 · 2016 [cited by applicant]
WO 2019115781A1 · 2019 [cited by applicant]
International Search Report (PCT/ISA/210) and Written Opinion (PCT/ISA/237) mailed on Jul. 28, 2020, by the European Patent Office as the International Searching Authority for International Application No. PCT/EP2020/06… [cited by applicant]
Ito, Shoei, et al., “A Simple Synthetic Method of trans-5-Aryl and 5-Cyclopropyl Derivatives of 2-Isoxazolin-4-ol via Intramolecular Ring Opening of α,β-Epoxy Ketone Oximes”. [cited by applicant]